Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at HC Wainwright

Evolus (NASDAQ:EOLS) had its price target reduced by HC Wainwright from $20.00 to $13.00 in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts have also weighed in on the company. BTIG Research reduced their price objective on Evolus from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Stifel Nicolaus reduced their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Finally, Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evolus has an average rating of “Moderate Buy” and an average target price of $18.17.

Evolus Stock Performance

NASDAQ:EOLS opened at $4.70 on Tuesday. Evolus has a fifty-two week low of $4.56 and a fifty-two week high of $17.12. The firm has a market cap of $304.65 million, a PE ratio of -5.11 and a beta of 1.11. The business has a 50 day moving average price of $6.16 and a 200-day moving average price of $6.76.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million during the quarter, compared to analysts’ expectations of $91.23 million. Research analysts predict that Evolus will post -0.61 EPS for the current year.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.10% of the stock is owned by insiders.

Institutional Trading of Evolus

Hedge funds have recently made changes to their positions in the business. Manchester Capital Management LLC purchased a new position in Evolus in the 2nd quarter worth about $26,000. State of Alaska Department of Revenue bought a new position in Evolus in the 3rd quarter worth about $26,000. Wexford Capital LP purchased a new position in shares of Evolus during the third quarter worth approximately $37,000. Aquatic Capital Management LLC purchased a new position in shares of Evolus during the third quarter worth approximately $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Evolus during the third quarter valued at approximately $62,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.